{
  "input": {
    "mode": "build_counterchain",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_tildrakizumab",
          "name": "Tildrakizumab"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_guselkumab",
          "name": "Guselkumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_apremilast",
          "name": "Apremilast"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 1
    },
    "constraints": {
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "n_ot_adalimumab",
          "type": "Target",
          "label": "Off-target Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_adalimumab",
          "type": "Pathway",
          "label": "Risk Pathway Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_adalimumab",
          "type": "Phenotype",
          "label": "Adverse Phenotype Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_adalimumab",
          "target": "n_ot_adalimumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能非特异性靶点影响"
        },
        {
          "source": "n_ot_adalimumab",
          "target": "n_rp_adalimumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路确立"
        },
        {
          "source": "n_rp_adalimumab",
          "target": "n_adv_adalimumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_adalimumab",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若此风险成立，药效可能受限"
        }
      ],
      "merge": [],
      "set_weights": [],
      "conflict_hotspots": [
        {
          "topic": "Adalimumab对皮肤免疫反应的影响",
          "pro_nodes": [
            "n_ot_adalimumab"
          ],
          "con_nodes": [
            "n_rp_adalimumab",
            "n_adv_adalimumab"
          ],
          "note": "短期缓解与长期并发症可能呈对立关系"
        }
      ]
    },
    "counterclaims": [
      {
        "id": "K1",
        "text": "若药物的非特异性作用真实存在，可能导致疗效下降",
        "confidence": "medium"
      },
      {
        "id": "K2",
        "text": "存在激活不良病理通路的风险，可能抵消临床预期效果",
        "confidence": "medium"
      }
    ],
    "assumptions_challenged": [
      "药物靶向机制是否足够专一",
      "潜在的免疫忽视与长期副作用"
    ],
    "falsification_tests": [
      "是否存在任何反映疗效的长期研究数据？",
      "是否有临床证据支持Adalimumab的安全使用？"
    ],
    "next_focus_for_pi": [
      "要求Proponent提供更多关于长期疗效与副作用的明确数据",
      "重新评估对可能副作用链的关注"
    ]
  }
}